drugset / Trial / NCT01591044

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

NCT01591044 ↗

Phase 2 Completed 301 enrolled Rigel Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.

Timeline

Start
2012-07
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator R-343 Small molecule 1 mg Inhaled
Comparator R-343 Small molecule 2 mg Inhaled

Indications